Revolutionizing Diabetes and Obesity Management: A Comprehensive Review of Tirzepatide’s Dual Agonist Approach

Sonam Samal, Sourav Maiti, Jonnalagadda Vihari

Abstract
Tirzepatide, an innovative glucagon-like peptide-1 (GLP-1) and glucagon receptor dual agonist, has emerged as a promising therapeutic avenue for type 2 diabetes and obesity management. This review encompasses a comprehensive evaluation of Tirzepatide’s mechanism of action, clinical efficacy, safety profile, and comparative effectiveness against existing treatments. By targeting multiple pathways related to glucose and weight regulation, Tirzepatide exhibits superior glycemic control and substantial weight loss, presenting a novel approach to address the intertwined challenges of diabetes and obesity. An analysis of pivotal clinical trials, potential adverse effects, and future directions in Tirzepatide research further underscores its potential as a transformative treatment strategy.

Keywords
Tirzepatide, Glucagon-like Peptide-1 (GLP-1), Glucagon Receptor, Dual Agonist, Diabetes, Obesity

Introduction
In recent years, the management of type 2 diabetes and obesity has witnessed a paradigm shift with the development of novel therapeutic agents targeting multiple pathways simultaneously.[1] Among these, tirzepatide, a dual agonist of the glucagon-like peptide-1 (GLP-1) and glucagon receptors, has garnered significant attention for its potential to address the intertwined challenges of hyperglycemia and excess weight. This review provides a comprehensive analysis of tirzepatide’s mechanism of action, clinical efficacy, safety profile, and comparative effectiveness against existing treatments.

Tirzepatide’s unique dual agonism offers a multifaceted approach to improving glycemic control and promoting weight loss. GLP-1 receptor activation stimulates insulin secretion, suppresses glucagon release, and enhances satiety, while glucagon receptor activation contributes to glycemic reduction without inducing excessive hypoglycemia. This dual targeting holds promise in achieving comprehensive metabolic benefits, setting tirzepatide apart from traditional monotherapies.

Clinical trials have demonstrated tirzepatide’s remarkable efficacy. In the SURPASS trials,[2] tirzepatide consistently achieved superior reductions in HbA1c and substantial weight loss across various patient populations, surpassing the outcomes observed with semaglutide and dulaglutide. Furthermore, tirzepatide’s favorable safety profile and side effect profile were evident in its well-tolerated gastrointestinal and cardiovascular profiles.

As the prevalence of type 2 diabetes and obesity continues to rise, tirzepatide presents a potential option for comprehensive management.
breakthrough in managing both conditions effectively. This review critically assesses the current evidence, evaluates its position in the existing therapeutic landscape, and explores future directions for research and clinical application.

**Discussion**

**Mechanism of Dual Agonism and Metabolic Benefits**

Tirzepatide’s dual agonism of the GLP-1 and glucagon receptors offers a novel approach to addressing the multifaceted challenges of type 2 diabetes and obesity. By activating GLP-1 receptors, tirzepatide enhances insulin secretion, suppresses glucagon release, and promotes feelings of satiety, contributing to improved glycemic control and reduced food intake. Simultaneously, activation of glucagon receptors leads to decreased hepatic glucose production, further aiding glycemic reduction without causing excessive hypoglycemia. This intricate interplay between dual agonism sets tirzepatide apart from conventional single-receptor-targeting therapies, potentially providing more comprehensive metabolic benefits.

**Clinical Efficacy and Comparative Effectiveness**

Clinical trials [Table-1], including the SURPASS trials, have demonstrated tirzepatide’s remarkable clinical efficacy. Superior reductions in HbA1c and substantial weight loss were consistently achieved across diverse patient populations. Tirzepatide’s outcomes surpassed those observed with semaglutide and dulaglutide, indicating its potential to establish a new standard of care. Furthermore, its efficacy was evident even in patients with long-standing diabetes and those who were treatment-experienced, highlighting its potential as a versatile therapeutic option.

**Safety Profile and Tolerability**

Tirzepatide’s safety profile is a pivotal aspect of its clinical utility. The well-tolerated gastrointestinal and cardiovascular profiles observed in trials underscore its potential for broader patient acceptance and long-term adherence. While gastrointestinal adverse events were reported, they were generally mild and transient. Additionally, the absence of increased cardiovascular risk is crucial, given the growing emphasis on cardiovascular safety in diabetes management. However, long-term post-marketing surveillance is essential to further ascertain its safety profile.

**Future Directions and Implications**

The emergence of tirzepatide offers a transformative avenue for diabetes and obesity management. Further research could explore optimal dosing regimens and patient selection criteria to maximize its benefits. Investigating its effects on diabetic complications, such as nephropathy and retinopathy, is also essential for comprehensive assessment. Additionally, comparative trials against emerging therapies and real-world evidence will contribute to refining its positioning in the treatment landscape.

**Regulatory Status of the Tirzepatide**

On May 13, 2022, the U.S. Food and Drug Administration granted approval for Mounjaro (tirzepatide) injection as an adjunct to diet and exercise to enhance blood sugar control in adults with type 2 diabetes. Eli Lilly & Company proposed the import and marketing of

<table>
<thead>
<tr>
<th>Table 1: Summary of Various Studies Conducted Globally On Tirzepatide.</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Study Name</strong></td>
</tr>
<tr>
<td>----------------</td>
</tr>
<tr>
<td>SURPASS-1[^6]</td>
</tr>
<tr>
<td>SURPASS-2[^7]</td>
</tr>
<tr>
<td>SURPASS-3[^1]</td>
</tr>
<tr>
<td>SURPASS-5[^1]</td>
</tr>
<tr>
<td>SURPASS-CVOT[^10]</td>
</tr>
<tr>
<td>REWIND[^11]</td>
</tr>
<tr>
<td>SURMOUNT-DM[^12]</td>
</tr>
<tr>
<td>SURMOUNT-OB[^13]</td>
</tr>
</tbody>
</table>
Tirzepatide [ND/IMP/23/000017] in India, accompanied by a global Phase-III clinical trial report, which included India as a participant. Following a thorough assessment during the 100th committee meeting on April 20-21, 2023, at CDSCO (HQ), New Delhi, the committee recommended granting permission for the import and marketing of Tirzepatide in various doses, subject to specific conditions. These conditions involve retail sales under the prescription of endocrinologists or internal medicine specialists and the requirement for the company to conduct a Phase-IV clinical trial, with the protocol submission within three months of drug approval. Notably, Tirzepatide [EMEA/H/C/005620] received marketing authorization in the European Union on September 15, 2022.\(^{[16]}\)

**Conclusion**

Tirzepatide’s dual agonist mechanism demonstrates a breakthrough in addressing the intertwined challenges of type 2 diabetes and obesity. Its multifaceted approach, coupled with its superior clinical efficacy and favorable safety profile, establishes it as a promising candidate for transforming current treatment strategies. The potential for improved glycemic control, substantial weight loss, and its distinctive dual targeting mechanism mark tirzepatide as a significant advancement in the field of metabolic therapeutics.

**Financial Support and Sponsorship**

Nil.

**Conflicts of Interest**

There are no conflicts of interest.

**References**


